Table 2. Differences in pathology outcomes between consolidation chemotherapy (CCT) and neoadjuvant chemoradiotherapy (nCRT).

	nCRT (n = 61)	CCT (n = 83)	P value
Interval time (weeks)
Median (range)	5 (3–14)	9 (2–16)	<0.001
<6	37 60.6%	9* 10.9%
6–10	20 32.7%	51 61.4%
>10	4 6.7%	23 27.7%
Approach
Laparoscopic	18 29.6%	40 48.1%	0.02
Open	43 70.4%	43 51.9%
Operation mode**
APR	31 50.8%	34 40.9%	0.16
LAR	20 32.7%	40 48.1%
Hartmann resection	10 16.5%	9 11%
Operation time (min)
Median (range)	215 (90–420)	210 (120–480)	0.53
Estimtated blood loss (g)
Median (range)	50 (20–100)	50 (20–500)	0.23
ypStage
0	3 4.9%	16 19.4%	0.008
I	12 19.7%	25 30.1%
II	25 41%	28 33.7%
III	21 34.4%	14 16.8%
ypTstage
0	3 4.9%	16 19.2%	0.001
1	3 4.9%	3 11%
2	11 18%	29 27.7%
3	5 8.3%	11 13.2%
4	39 63.9%	24 28.9%
ypNstage
0	40 65.5%	69 83.1%	0.11
1	12 19.6%	8 9.6%
2	9 5.9%	6 7.3%
pCR rate	3 4.9%	16 19.3%	0.01
DS rate (ypStage 0 + I)	15 24.6%	38 45.8%	0.009

Notes:

^*Nine patients had only one cycle of the XELOX because they refused the second cycle of XELOX.

^**Patients with T4b tumors with adjacent organ invasion underwent combined resection.

APR, abdominoperineal resection; LAR, low anterior resection; pCR, pathologic complete response; DS, downstaging.